rongmiao zhou

Dr. rongmiao zhou

the fourth hospital of hebei medical university, Shijiazhuang, Hebei, China
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YLYuekao Li
Yuekao Li
CNChaoxu Niu
Chaoxu Niu
NWNa Wang
Na Wang
XHXi Huang
Xi Huang
SCShiru Cao
Shiru Cao
RZrongmiao zhou
rongmiao zhou
N6-methyladenosine (m6A) modification, the most prevalent RNA modification, is involved in all aspects of RNA metabolism, including RNA processing, nuclear export, stability, translation and degradation. Therefore, m6A modification can participate in various physiological functions, such as tissue development, heat shock response, DNA damage response, circadian clock control and even in carcinogenesis through regulating the expression or structure of the gene. The deposition, removal and recognition of m6A are carried out by methyltransferases, demethylases and m6A RNA binding proteins, respectively. Aberrant m6A modification and the dysregulation of m6A regulators play critical roles in the occurrence and development of various cancers. The pathogenesis of esophageal cancer (ESCA) remains unclear and the five-year survival rate of advanced ESCA patients is still dismal. Here, we systematically reviewed the recent studies of m6A modification and m6A regulators in ESCA and comprehensively analyzed the role and possible mechanism of m6A modification and m6A regulators in the occurrence, progression, remedy and prognosis of ESCA. Defining the effect of m6A modification and m6A regulators in ESCA might be helpful for determining the pathogenesis of ESCA and providing some ideas for an early diagnosis, individualized treatment and improved prognosis of ESCA patients.

5 February 2014 in Biomarkers
Verified
Journal Article
Closed access
PDF file
LYLi Yan
Li Yan
PHPei Hu
Pei Hu
YCYu Cao
Yu Cao
GWGuiying Wang
Guiying Wang
WNWang Na
Wang Na
RZrongmiao zhou
rongmiao zhou
Background: In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC). Methods: A total of 10 studies consist of 1479 EOC patients relating ERCC1 rs11615C/T and rs3212986C/A polymorphisms to the response of platinum-based chemotherapy were included in this meta-analysis. Results: The analysis showed that the AA genotype of the rs3212986C/A polymorphism in ERCC1 was associated with progression-free survival of EOC patients (HR = 1.39, 95% CI = 1.12–1.73) and that the CA or AA genotypes could influence overall survival (HR = 1.28, 95% CI = 1.05–1.56; and HR = 1.55, 95% CI = 1.17∼2.05, respectively). Conclusions: The ERCC1 rs3212986C/A polymorphism may be a useful prognostic marker in platinum-based treatment of EOC.

1 September 2006
Verified
Journal Article
Closed access
RZrongmiao zhou
rongmiao zhou
YLYan Li
Yan Li
NWNa Wang
Na Wang
XZXiao-Juan Zhang
Xiao-Juan Zhang
XDXiu-Juan Dong
Xiu-Juan Dong
WGWei Guo
Wei Guo

1 November 2013
Verified
Journal Article
Closed access
BQBing-Li Qi
Bing-Li Qi
YLYan Li
Yan Li
NWNa Wang
Na Wang
RZrongmiao zhou
rongmiao zhou
PHPei Hu
Pei Hu
SKShan Kang
Shan Kang

13 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MLMeitong Liu
Meitong Liu
YZYaning Zhao
Yaning Zhao
ZXZhuoyun Xiao
Zhuoyun Xiao
RZrongmiao zhou
rongmiao zhou
XCXiaodong Chen
Xiaodong Chen
NWNa Wang
Na Wang
We aimed to explore the effect of CD39 expression on CD8+ T cells and on the diagnosis and prognosis of esophageal squamous cell carcinoma (ESCC). The independent prognostic factors for the surgical specimens of the 95 ESCC patients were screened by multivariate Cox regression analysis. Differential gene expression analysis was performed by the NetworkAnalyst platform based on data from the Gene Expression Omnibus (GEO). The expression of CD39 on CD8+ T cells in the CK+ region was higher in cancer tissue than in paracancerous tissue (p = 0.011), and high CD39-expressing CD8+ T cells in the CK+ region (HR, 2.587; p = 0.033) and high CD39-expressing CD8+ T cells in the CK− region (HR, 3.090; p = 0.008) were independent risk factors for prognosis in ESCC patients; the expression of ENTPD1 was upregulated in ESCC tissues compared to normal tissues (adjusted p < 0.001; log2 fold change = 1.99), and its expression was significantly positively correlated with the expression of PDCD1, CTLA4, and HAVCR2. High CD39-expressing CD8+ T cells can be used as a new molecular marker for the diagnosis and prognosis of ESCC, and the restoration of partially exhausted CD8+ T cells by inhibiting CD39 may be a new strategy for treating ESCC.

2 February 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
RZrongmiao zhou
rongmiao zhou
YLYan Li
Yan Li
NWNa Wang
Na Wang
CNChaoxu Niu
Chaoxu Niu
XHXi Huang
Xi Huang
XHXiangran Huo
Xiangran Huo